Market Closed

ROIV
Roivant Sciences Ltd.
$ 39.53
-1.15%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago

Roivant Sciences Ltd. News

Latest Roivant Sciences Ltd. Stock News & ROIV Headlines

Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
4 days ago | globenewswire.com
Roivant Sciences Ltd. $ROIV Stock: CenterBook Partners LP Cuts Position
5 days ago | defenseworld.net
Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
5 days ago | seekingalpha.com
Roivant Sciences Q2 Earnings Call Highlights
5 days ago | marketbeat.com
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
5 days ago | zacks.com
Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares
8 days ago | defenseworld.net
Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares
8 days ago | defenseworld.net
Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript
24 days ago | seekingalpha.com
Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
24 days ago | marketbeat.com
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
25 days ago | globenewswire.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

ROIV
Roivant Sciences Ltd.
$ 39.53
-1.15%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago